ZEALAND PHARMA A/S

ZEAL
Delayed Quote. Delayed  - 11/26 10:59:32 am
142.8DKK -1.65%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
Zealand Pharma A/S is a Denmark-based biopharmaceutical company engaged in the discovery, development and commercialization of peptide-based medicines. The Company's pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and Danegaptide. The Other indications area offers ZP1848, Elsiglutide and ZP1480 (ABT-719) drugs for inflammatory bowel disease, chemotherapy-induced diarrhea and acute kidney injury treatment. Furthermore, the Company collaborates with a number of partners, such as Sanofi, Helsinn, Boehringer Ingelheim, Abbvie and Eli Lilly.

Number of employees : 329 people.
Sales per Business
20192020
Peptide-based Medicines41.33100%353.31100%
DKK in Million
Sales per region
20192020
Denmark41.33100%353.31100%
DKK in Million
Managers
Name Title
Emmanuel Dulac President & Chief Executive Officer
Matthew D. Dallas Chief Financial Officer & Senior Vice President
Alf Gunnar Martin Nicklasson Chairman
Adam Sinding Steensberg Chief Medical Officer, EVP-Research & Development
Danilo Verge Head-Global Medical Affairs
Ivan M. Mřller Senior VP-Technical Development & Operations
Michael John Owen Independent Director
Kirsten Aarup Drejer Vice Chairman
Alain H. Munoz Independent Director
Bernadette Mary Connaughton Independent Director
Shareholders
Name Equities %
Van Herk Investments BV 7,299,832 16.7%
Capital Research & Management Co. (World Investors) 2,414,836 5.54%
Wellington Management Co. LLP 1,892,845 4.34%
Polar Capital LLP 1,873,341 4.30%
Credit Suisse Asset Management (Schweiz) AG 1,769,728 4.06%
The Vanguard Group, Inc. 1,187,844 2.73%
Swedbank Robur Fonder AB 1,187,200 2.72%
Norges Bank Investment Management 1,028,229 2.36%
T. Rowe Price International Ltd. 961,441 2.21%
Handelsbanken Fonder AB 784,051 1.80%
Sector Bio Therapeutic Drugs
1st jan.Capi. (M$)
ZEALAND PHARMA A/S-40.57%946
GILEAD SCIENCES, INC.20.61%87 895
BIONTECH SE326.89%73 606
REGENERON PHARMACEUTICALS33.17%67 771
WUXI APPTEC CO., LTD.24.40%62 328
VERTEX PHARMACEUTICALS-22.32%47 352
BEIGENE, LTD.34.56%32 981
GENMAB A/S5.85%25 833
ARGENX SE1.82%14 272
ACCELERON PHARMA INC.39.71%10 932
ASCENDIS PHARMA A/S-13.77%8 360
NEUROCRINE BIOSCIENCES, INC.-9.25%8 335
HUALAN BIOLOGICAL ENGINEERING INC.-31.75%8 327
MIRATI THERAPEUTICS, INC.-37.73%7 796
ARROWHEAD PHARMACEUTICALS, INC.-6.14%7 739
LEGEND BIOTECH CORPORATION92.26%7 321
SAREPTA THERAPEUTICS, INC.-52.50%7 051
GW PHARMACEUTICALS PLC89.72%6 907
REMEGEN CO., LTD.10.63%6 848
DENALI THERAPEUTICS INC.-46.25%5 818
BIOCON LIMITED-22.11%5 788
Brand Portfolio
ZEALAND PHARMA
ZEALAND PHARMA
» More brands of Zealand Pharma A/S